Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BFRGW
Upturn stock ratingUpturn stock rating

Bullfrog AI Holdings, Inc. Warrants (BFRGW)

Upturn stock ratingUpturn stock rating
$0.57
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BFRGW (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $

1 Year Target Price $

Analysts Price Target For last 52 week
$Target price
Low$
Current$0.57
high$

Analysis of Past Performance

Type Stock
Historic Profit 61.76%
Avg. Invested days 72
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 0.14 - 1.37
Updated Date 02/26/2025
52 Weeks Range 0.14 - 1.37
Updated Date 02/26/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bullfrog AI Holdings, Inc. Warrants

stock logo

Company Overview

overview logo History and Background

Bullfrog AI Holdings, Inc. is a biotechnology company focused on using artificial intelligence and machine learning to improve drug development. The warrants represent the right to purchase shares of Bullfrog AI Holdings, Inc. at a specified price and date. Bullfrog AI Holdings, Inc. went public on January 4, 2024, and trades on the Nasdaq market.

business area logo Core Business Areas

  • Artificial Intelligence: Developing and applying AI/ML technologies to analyze complex data sets in drug development and precision medicine.
  • Drug Development: Partnering with pharmaceutical companies to improve drug efficacy and reduce development costs through AI-driven insights.
  • Biotechnology: Utilizing bioinformatics and computational biology to advance healthcare solutions.

leadership logo Leadership and Structure

The leadership team includes experts in AI, biotechnology, and drug development. The organizational structure consists of departments focusing on AI research, data analysis, drug development partnerships, and business development.

Top Products and Market Share

overview logo Key Offerings

  • bfLEAPu2122: bfLEAP is Bullfrog AI's proprietary AI/ML platform designed to identify actionable insights from complex biological data. It helps predict drug efficacy, identify patient subgroups that respond to therapy, and optimize clinical trials. Market share data is not publicly available due to the niche nature of the offering. Competitors include companies offering similar AI platforms for drug discovery and development, such as Schrodinger, Exscientia, and Recursion Pharmaceuticals.

Market Dynamics

industry overview logo Industry Overview

The biotechnology and AI-driven drug discovery industry is rapidly growing, driven by the increasing complexity of biological data and the need for more efficient drug development processes. There is a strong emphasis on personalized medicine and precision diagnostics.

Positioning

Bullfrog AI positions itself as an innovator in AI-driven drug development, focusing on improving clinical trial outcomes and personalized medicine. Their competitive advantage lies in the bfLEAPu2122 platform's unique capabilities.

Total Addressable Market (TAM)

The total addressable market for AI in drug discovery is projected to reach billions of dollars. Bullfrog AI is positioned to capture a segment of this market by providing their proprietary AI platform and expertise to pharmaceutical and biotech companies.

Upturn SWOT Analysis

Strengths

  • Proprietary AI platform (bfLEAPu2122)
  • Expertise in AI/ML and biotechnology
  • Focus on precision medicine
  • Partnerships with pharmaceutical companies

Weaknesses

  • Limited financial resources compared to larger competitors
  • Reliance on partnerships for revenue generation
  • Relatively small market capitalization
  • Relatively new company

Opportunities

  • Expanding partnerships with pharmaceutical companies
  • Developing new AI-driven applications for drug discovery
  • Entering new markets
  • Advancements in AI and machine learning
  • Increase adoption of precision medicine

Threats

  • Competition from larger companies with more resources
  • Regulatory hurdles in drug development
  • Rapid technological advancements that could render their AI platform obsolete
  • Failure of clinical trials

Competitors and Market Share

competitor logo Key Competitors

  • SCHR
  • RXRX
  • CRSP

Competitive Landscape

Bullfrog AI competes with larger companies that have established AI platforms and extensive resources. Their competitive advantage lies in the specialized application of their AI platform to precision medicine and drug development, which allows them to offer tailored solutions.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the company's recent establishment. However, the company shows strong initial interest from pharma partners.

Future Projections: Future growth is dependent on the success of their partnerships, adoption of the bfLEAPu2122 platform, and ability to secure funding. Analyst estimates are not widely available at this stage.

Recent Initiatives: Recent initiatives include forging new partnerships with pharmaceutical companies and expanding the capabilities of the bfLEAPu2122 platform.

Summary

Bullfrog AI Holdings, Inc. Warrants represent a speculative investment tied to a biotechnology company with a promising AI platform. The company shows potential due to its focus on precision medicine and partnerships with pharmaceutical companies. However, it faces risks associated with competition, regulatory hurdles, and dependence on successful clinical trials. Investors should carefully evaluate the risks and potential rewards before investing in the warrants.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Market Analysis Reports
  • Press Releases

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence. Financial data is based on preliminary estimates and may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bullfrog AI Holdings, Inc. Warrants

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-02-14
CEO -
Sector Healthcare
Industry Health Information Services
Full time employees 2
Website
Full time employees 2
Website

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.